Pharmaceutical Technology

JUNE 7, 2023

AstraZeneca has announced it would stop Andexxa’s Phase IV trial after the study achieved its aims earlier than expected. The ANNEXA-I study (NCT03661528) was designed to assess the use of Andexxa (adexanet alfa) in patients on an oral Factor Xa (FXa) inhibitor treatment including Eliquis (apixaban), which is marketed in the US by Pfizer and Bristol Myers Squibb , and Janssen’s Xarelto (rivaroxaban), who were experiencing an intracranial haemorrhage.

Trials 264

Trials Drugs Marketing 264

Bio Pharma Dive

JUNE 7, 2023

Co-founded by Stanford University professor Irv Weissman, the company debuted with $145 million and plans to use CD47 antibodies, best known as potential cancer immunotherapies, to reduce the risk of heart attacks.

Antibody 246

Antibody 246

Pharmaceutical Technology

JUNE 7, 2023

Eli Lilly has achieved significant gains in the past quarter, leading to it becoming the most valuable pharmaceutical company in the world, with a market cap of $420bn, surpassing Johnson & Johnson. The recent rallying of Lilly’s market value has come as the result of two major announcements: its blockbuster type 2 diabetes (T2D) drug Mounjaro (tirzepatide) successfully completed its second final-stage trial for obesity, and its experimental treatment for Alzheimer’s disease completed its Ph

Drugs 246

Drugs Trials Marketing Sales 246

AuroBlog - Aurous Healthcare Clinical Trials blog

JUNE 7, 2023

Dr K Sujith Kumar, the senior deputy drugs controller (DDC) at the department of drugs control administration (DCA) in Kerala has been appointed as the drug controller-in-charge of the state from Thursday, June, 1. A Ph D holder in Pharmaceutical Regulatory Affairs (PRA) from the JSS University in Mysore, Dr.

Drugs 203

Drugs Clinical Trials Clinical Trials Clinical Research 203

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Pharmaceutical Technology

JUNE 7, 2023

ZyVersa Therapeutics has received a notice of intention to grant from the European Patent Office for its patent application for the cholesterol efflux mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin). The application was filed for the treatment of diabetic nephropathy/diabetic kidney disease. The Phase IIa-ready VAR 200 is being developed to reduce renal cholesterol and the lipid accumulation that damages the filtration system of kidneys in glomerular diseases patients.

Clinical Trials 246

Clinical Trials Clinical Trials Trials Development 246

AuroBlog - Aurous Healthcare Clinical Trials blog

JUNE 7, 2023

Researchers have recently shown that separate mechanisms drive the hallucinogenic and antidepressant effects of psychedelics like LSD and psilocin, potentially paving the way to use these ‘party drugs’ as treatments that don’t trigger psychedelic trips.

Drugs 182

Drugs Research Clinical Trials Clinical Trials 182

Bio Pharma Dive

JUNE 7, 2023

Briefing documents released Wednesday indicate agency staff seem confident in the drug’s benefits and the ability to mitigate its associated safety risks.

Drugs 176

Drugs 176

Pharmaceutical Technology

JUNE 7, 2023

Clinical-stage biotechnology company Acepodia has raised $100m in a Series D financing round to advance the first-in-class cell therapies being developed using the antibody-cell conjugation (ACC) platform. The financing round, led by Digital Mobile Venture, has also seen participation from other existing investors. The latest funding brings the total venture capital financing secured by the company so far to $259m.

Gene Therapy 147

Gene Therapy Gene Antibody Trials 147

Rethinking Clinical Trials

JUNE 7, 2023

Dr. Shirley Wang In this Friday’s PCT Grand Rounds, Shirley Wang of Harvard Medical School will present “Emulating Randomized Clinical Trials With Non-randomized Real-World Evidence Studies: Results From the RCT DUPLICATE Initiative.” The Grand Rounds session will be held on Friday, June 9, 2023, at 1:00 pm eastern. The DUPLICATE initiative is building an empirical evidence base for using longitudinal insurance claims prospectively to achieve large-scale replication of randomiz

Clinical Trials 130

Clinical Trials Clinical Trials Trials Medicine 130

Pharmaceutical Technology

JUNE 7, 2023

Baudax Bio revealed has additional results from a Phase II trial investigating its neuromuscular blockade (NMD) agent BX1000 in patients undergoing elective surgery demonstrating favourability to rocuronium. The company now plans to combine it with its pipeline reversal blocking agent. Shares in the US-based company previously surged after the topline data reveal in April.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Drugs 130

Advertisement

There’s been a rapid shift towards decentralization in clinical trials & it’s clear why. The potential for reaching a larger pool of recruits is possible when sponsors can bring more trial activities to the patient. Tele visits, digital consent, new monitoring sensors, & direct-to-patient supply are virtual tools that existed before the pandemic, but now there’s swift adoption of these methods because they’ve been proven to help launch & complete trials more effectively.

Trials

Bio Pharma Dive

JUNE 7, 2023

Despite the setback, FibroGen could still rebound later this year if a study in earlier-stage Duchenne patients, who can still walk, is successful.

Trials 144

Trials Drugs 144

Pharmaceutical Technology

JUNE 7, 2023

Covid-19 vaccine compositions should be updated to provide protection against XBB Omicron variant strains in preparation for the autumn vaccination campaign, say EU agencies in a joint 6 June statement. This reflects decisions made at past meetings by members of the International Coalition of Medicines Regulatory Authorities on 8 May and elsewhere. There, organisations determined that the compositions of Covid-19 vaccines need to be updated to reflect the evolution of the virus.

Vaccination 130

Vaccination Vaccine Medicine Manufacturing 130

Bio Pharma Dive

JUNE 7, 2023

Companies have had 10 years to comply with the Drug Supply Chain Security Act, but some fear the industry is not ready for a Nov. 27 deadline.

Drugs 130

Drugs 130

Pharmaceutical Technology

JUNE 7, 2023

The US Food and Drug Administration (FDA) has accepted GSK’s supplemental biologics licence application (sBLA) for its Jemperli (dostarlimab) plus chemotherapy for priority review. The company is seeking approval for the combination therapy to treat mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in adult patients.

Antibody 130

Antibody Drugs Trials Development 130

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

Fierce Pharma

JUNE 7, 2023

Merck has taken the lead, filing a lawsuit seeking to overturn drug pricing measures in the Inflation Reduction Act (IRA). | Merck has filed a lawsuit seeking to overturn drug-pricing measures in the Inflation Reduction Act (IRA). Now, emboldened by the New Jersey drugmaker, other biopharma CEOs are making their concerns known. At the BIO International Convention, Biogen CEO Chris Viehbacher registered severe criticism of the IRA and said his company was considering filing its own lawsuit.

Drugs 129

Drugs 129

Pharmaceutical Technology

JUNE 7, 2023

The European Commission (EC) has granted marketing authorisation for Fennec Pharmaceuticals’ Pedmarqsi (sodium thiosulfate) to reduce the risk of hearing loss in paediatric oncology patients. Known as Pedmark in the US, Pedmarqsi is the first and only therapy to receive approval in the European Union to prevent cisplatin chemotherapy-induced hearing loss (ototoxicity) in patients aged between one month and 18 years with localised, non-metastatic solid tumours.

Marketing 130

Marketing Medicine Trials Production 130

Rethinking Clinical Trials

JUNE 7, 2023

                                            Speaker John Alexander, MD, MHS Professor of Medicine/Cardiology DCRI/Duke University Slides Keywords PROACT Xa, Aortic Valve Replacement, Warfarin, Apixaban, Pragmatic Clinical Trial Key Points In the PROACT Xa trial, researchers wanted to learn if patients with an On-X mech valve implanted in the aortic position can be maintained on a factor Xa inhibitor (Apixaban) with a safe level of thromboembolic events

Clinical Trials 130

Clinical Trials Clinical Trials Trials Drugs 130

Pharmaceutical Technology

JUNE 7, 2023

The US Food and Drug Administration (FDA) has granted approval for a new indication for Merck’s PREVYMIS (letermovir) to prevent cytomegalovirus (CMV) disease in high-risk adult kidney transplant recipients. The latest move follows a priority review of a supplemental new drug application (sNDA) for the therapy. In 2017, the therapy received FDA approval for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant.

FDA Approval 130

FDA Approval Clinical Development Drugs Medicine 130

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

Clinical Research

Fierce Pharma

JUNE 7, 2023

As Alzheimer's disease partners Eisai and Biogen lay the groundwork for a wider launch of Leqembi, their efforts center on winning a full FDA approval. | As Alzheimer's partners Eisai and Biogen lay the groundwork for a wider launch of Leqembi, their efforts center on winning a full FDA approval. On Wednesday, that vision came into better focus as the FDA released a document showing how the agency views the drug.

FDA Approval 117

FDA Approval Drugs 117

XTalks

JUNE 7, 2023

In the dynamic and ever-evolving food and beverage industry, growth is not just about size; it’s about speed, too. The fastest growing beverage brands are those that have tapped into the consumer’s evolving demands, bringing to the table innovative products that combine taste, convenience, affordability and sustainability. The following list is based on the Financial Times’ ranking of The Americas’ Fastest-Growing Companies 2023 , a list of the 500 companies in the Americas that hav

Branding 98

Branding Production Marketing Research 98

Fierce Pharma

JUNE 7, 2023

The rush to provide revolutionary weight-loss drugs to obese patients has reached the U.K. | The rush to provide revolutionary weight-loss drugs to obese patients has reached the U.K. On Wednesday, the government unveiled a two-year pilot program that will allow Novo Nordisk’s Wegovy to be given to more overweight participants, even though the treatment has yet to be launched there.

Drugs 110

Drugs 110

BioPharma Reporter

JUNE 7, 2023

Adede is a seasoned computer scientist and data professional known for providing high quality service whilst employing her multi talents which include efficiency, analytical thinking, and fast learning.

Scientist 98

Scientist Regulation Marketing 98

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

Fierce Pharma

JUNE 7, 2023

As pharma supply chain problems drag on, a shortage of key cancer drugs has afflicted a large number of treatment centers and many patients. | The National Comprehensive Cancer Network's recent survey shows that nearly all of the treatment centers it polled are facing a carboplatin shortage. Meanwhile, 70% of them reported a cisplatin shortage.

Drugs 106

Drugs 106

Antidote

JUNE 7, 2023

Before any new medical treatment, therapy, or device is approved, it must first be tested through clinical research studies. While some research studies seek participants with illnesses or conditions to be studied in the clinical trial, it is not always necessary to have a specific illness or condition to participate. In fact, there are many trials that need healthy volunteers.

Research 97

Research Clinical Trials Clinical Trials Clinical Research 97

pharmaphorum

JUNE 7, 2023

With a 51% reduction in deaths, AstraZeneca’s ADAURA trial was one of the breakout stories of this year’s ASCO. In Chicago, Editor in Chief Jonah Comstock was able to sit down with AstraZeneca Head of Lung Cancer Commercial Arun Krishna to dive in a little bit on this practice-changing study.

Trials 96

Trials 96

Cloudbyz

JUNE 7, 2023

The medical technology (MedTech) industry has been witness to revolutionary changes over the last few years. These transformations have been fueled by a mix of technological innovation, policy changes, and shifts in healthcare delivery. One such significant development shaping the future of the MedTech sector is the adoption of Real-World Evidence (RWE).

Clinical Trials 96

Clinical Trials Clinical Trials Trials Medicine 96

Advertiser: FourKites

A research study conducted by The Journal of Commerce and FourKites surveyed hundreds of international shippers, exploring how their usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19. For international shippers, ocean freight visibility has evolved from optional to essential and satisfaction with visibility varies greatly depending on how it is obtained and delivered.

Research

BioSpace

JUNE 7, 2023

In a late-stage study of non-ambulatory patients with DMD on background corticosteroids, pamrevlumab failed to meet the primary endpoint for upper limb performance.

Trials 98

Trials Drugs 98

Fierce Pharma

JUNE 7, 2023

Legend Biotech and Johnson & Johnson are moving fast in their efforts to forward their CAR-T standout Carvykti. | Legend Biotech and Johnson & Johnson have filed with the FDA for expanded use of Carvykti. After gaining approval 16 months ago for the CAR-T to treat multiple myeloma patients following four or more lines of therapy, the companies hope to get the U.S. regulator to sign off on its use at an earlier stage of treatment.

Trials 95

Trials Regulation 95

BioSpace

JUNE 7, 2023

Promosome filed lawsuits Tuesday against Moderna and Pfizer/BioNTech, alleging that the vaccine developers used patent-protected mRNA technology without a license.

Vaccination 97

Vaccination Vaccine Licensing Licensing 97

Fierce Pharma

JUNE 7, 2023

After GSK nabbed a coveted world-first approval for its adult respiratory syncytial virus (RSV) vaccine in the U.S., it has scored the same title in Europe with Arexvy. | After scoring its world-first approval in May, GSK's RSV vaccine for older adults bagged a nod in Europe. The company and its rivals are gearing up to launch their products ahead of the fall RSV season.

Vaccination 89

Vaccination Vaccine Production 89

Speaker: Steve Goldstein, Sales Leader

Are you currently in sales, or involved in a business that depends on strong sales results? What about the extremely competitive world of medical device sales? What are some of the top challenges your customers face and how do you approach understanding what’s most important to them? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC., to discover critical strategies and approaches you can take to engage your customers, achieve g

Sales